Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (431-440 of 525) with videos related to

Pageof 53
Sort By:
African Health Sciences|October 25, 2017
Demographic and epidemiological characteristics of HIV opportunistic infections among older adults in NigeriaJoshua O Akinyemi, Babatunde O Ogunbosi, Adetona S Fayemiwo, et al.
Antimicrobial Agents and Chemotherapy|December 16, 2015
Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved SurvivalNathaniel J Rhodes, Joseph L Kuti, David P Nicolau, et al.
American Journal of Clinical Pathology|February 4, 2017
An Essential Pathology Package for Low- and Middle-Income CountriesKenneth A Fleming, Mahendra Naidoo, Michael Wilson, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2020
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumoniaLuzelena Caro, David P Nicolau, Jan J De Waele, et al.
International Journal of Antimicrobial Agents|February 10, 2021
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal ClearanceDavid P Nicolau, Jan De Waele, Joseph L Kuti, et al.
Tropical Medicine and Infectious Disease|April 27, 2023
Asymptomatic and Mild SARS-CoV-2 Infections in a Hungarian Outpatient Cohort in the First Year of the COVID-19 PandemicIstván Jankovics, Cecília Müller, Éva Gönczöl, et al.
Reproductive Health|June 11, 2009
National data system on near miss and maternal death: shifting from maternal risk to public health impact in NigeriaOlufemi T Oladapo, Olalekan O Adetoro, Oluwarotimi Fakeye, et al.
Diagnostic Microbiology and Infectious Disease|April 18, 2018
Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbationsJoseph L Kuti, Rebecca S Pettit, Natalie Neu, et al.
Diagnostic Microbiology and Infectious Disease|May 25, 2015
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosisJoseph L Kuti, Rebecca S Pettit, Natalie Neu, et al.
Health Research Policy and Systems|June 27, 2013
Establishing a national influenza sentinel surveillance system in a limited resource setting, experience of Sierra LeoneSenait Kebede, Ishata N Conteh, Christoph A Steffen, et al.
Pageof 53

Showing results (431-440 of 525) with videos related to

Sort By:
Pageof 53
African Health Sciences|October 25, 2017
Demographic and epidemiological characteristics of HIV opportunistic infections among older adults in NigeriaJoshua O Akinyemi, Babatunde O Ogunbosi, Adetona S Fayemiwo, et al.
Antimicrobial Agents and Chemotherapy|December 16, 2015
Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved SurvivalNathaniel J Rhodes, Joseph L Kuti, David P Nicolau, et al.
American Journal of Clinical Pathology|February 4, 2017
An Essential Pathology Package for Low- and Middle-Income CountriesKenneth A Fleming, Mahendra Naidoo, Michael Wilson, et al.
The Journal of Antimicrobial Chemotherapy|March 27, 2020
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumoniaLuzelena Caro, David P Nicolau, Jan J De Waele, et al.
International Journal of Antimicrobial Agents|February 10, 2021
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal ClearanceDavid P Nicolau, Jan De Waele, Joseph L Kuti, et al.
Tropical Medicine and Infectious Disease|April 27, 2023
Asymptomatic and Mild SARS-CoV-2 Infections in a Hungarian Outpatient Cohort in the First Year of the COVID-19 PandemicIstván Jankovics, Cecília Müller, Éva Gönczöl, et al.
Reproductive Health|June 11, 2009
National data system on near miss and maternal death: shifting from maternal risk to public health impact in NigeriaOlufemi T Oladapo, Olalekan O Adetoro, Oluwarotimi Fakeye, et al.
Diagnostic Microbiology and Infectious Disease|April 18, 2018
Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbationsJoseph L Kuti, Rebecca S Pettit, Natalie Neu, et al.
Diagnostic Microbiology and Infectious Disease|May 25, 2015
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosisJoseph L Kuti, Rebecca S Pettit, Natalie Neu, et al.
Health Research Policy and Systems|June 27, 2013
Establishing a national influenza sentinel surveillance system in a limited resource setting, experience of Sierra LeoneSenait Kebede, Ishata N Conteh, Christoph A Steffen, et al.
Pageof 53